Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease
source: Clinical Infectious Diseases
year: 2017
authors: Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M
summary/abstract:Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed dose combination, ledipasvir and sofosbuvir for 12 weeks in this population.
organization: Johns Hopkins University School of Medicine, Baltimore; Gilead Sciences, Inc., Foster City USADOI: 10.1093/cid/cix441
read more full text
+myBinderRelated Content
-
Stable engraftment with haploidentical peripheral blood stem cell transplantation in adult patients with sickle cell...The widespread application of allogeneic...
-
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
-
Novel use of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemiaHydroxyurea treatment is recommended for...
-
At 16, She’s a Pioneer in the Fight to Cure Sickle Cell DiseaseHelen Obando, a shy slip of a girl, lay ...
-
Genetic Treatments for Sickle CellFor decades physicians have known that a...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.